Artificial intelligence (AI) is rapidly reshaping pharmaceutical research and development (R&D), promising faster drug discovery and more personalised therapies. Yet, as the technology becomes increasingly central to the industry, experts are questioning who ultimately benefits from these advances.
Pharmaceutical companies are leveraging AI to analyse massive datasets, identify potential drug candidates, and streamline clinical trials. Proponents say this could reduce development timelines from over a decade to just a few years, potentially lowering costs and accelerating patient access to new treatments.
“AI allows us to see patterns in data that were previously impossible to detect,” said Dr Angela Martinez, Chief Scientific Officer at BioNova, a biotech firm pioneering AI-driven drug discovery. “This could revolutionise the way we approach complex diseases.”
However, critics caution that the benefits may be unevenly distributed. While major pharmaceutical firms gain efficiency and market advantages, smaller companies and patients may not see comparable gains. Some ethicists also warn that prioritising profitability over equitable access could deepen healthcare disparities.
“Technological breakthroughs do not automatically translate to better outcomes for everyone,” said Prof. Samuel Okoye, a bioethics expert at the University of Lagos. “We need policies that ensure AI-driven innovations serve public health, not just corporate interests.”
Regulators are starting to explore frameworks for responsible AI use in pharma, balancing innovation with safety and accessibility. Meanwhile, industry stakeholders are debating the ethical and economic implications, highlighting the tension between technological promise and societal benefit.
As AI continues to gain traction in pharmaceutical R&D, the conversation over who benefits-and who may be left behind-is likely to intensify.
Senior Reporter/Editor
Bio: Ugochukwu is a freelance journalist and Editor at AIbase.ng, with a strong professional focus on investigative reporting. He holds a degree in Mass Communication and brings extensive experience in news gathering, reporting, and editorial writing. With over a decade of active engagement across diverse news outlets, he contributes in-depth analytical, practical, and expository articles exploring artificial intelligence and its real-world impact. His seasoned newsroom experience and well-established information networks provide AIbase.ng with credible, timely, and high-quality coverage of emerging AI developments.